Pacira BioSciences (PCRX) Cash from Financing Activities (2010 - 2026)

Pacira BioSciences' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$59.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 1883.9% year-over-year to -$59.4 million; the TTM figure through Mar 2026 stood at -$426.0 million (down 2578.94% YoY), while the FY2025 annual figure was -$369.6 million, down 2228.82% from the prior year.
• Cash from Financing Activities was -$59.4 million for Q1 2026 at Pacira BioSciences, down from -$51.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $25.0 million in Q2 2024 to a low of -$257.5 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged -$58.6 million across 5 years, with a median of -$27.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 5577.27% in 2024, then tumbled 8950.12% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$58.5 million in 2022, then soared by 96.96% to -$1.8 million in 2023, then declined by 9.89% to -$2.0 million in 2024, then tumbled by 2542.05% to -$51.7 million in 2025, then fell by 15.0% to -$59.4 million in 2026.
• The last three Cash from Financing Activities figures came in at -$59.4 million (Q1 2026), -$51.7 million (Q4 2025), and -$257.5 million (Q3 2025), per Business Quant data.